Patients in the control group were treated with neoadjuvant androgen suppression with leuprorelin ( @ mg every @ months , intramuscularly ) for @ months ( short-term ) and radiotherapy alone ( designated STAS ) ; this procedure was either followed by another @ months of androgen suppression with leuprorelin ( intermediate-term ; ITAS ) or accompanied by @ months of zoledronic acid ( @ mg every @ months for @ months , intravenously ; STAS plus zoledronic acid ) or by both ( ITAS plus zoledronic acid ) .